Evaluation of Herpes Simplex Virus 1 Thymidine Kinase-Mediated Trapping of 131I FIAU and Prodrug Activation of Ganciclovir as a Synergistic Cancer Radio/Chemotherapy

Abstract

Evaluation of selective killing of Herpes Simplex Virus 1 thymidine kinase (HSV1-tk) expressing tumors by radiolabeled 131I-fialuridine (FIAU), and of synergy between 131I-FIAU and Ganciclovir (GCV). HSV1-tk-expressing cell lines and parental cell lines were exposed to 131I-FIAU alone, GCV alone, or combinations. Activity and concentration were varied widely, concurrent and sequential administrations tested, and dose rate effects were studied. HSV1-tk-expressing cells accumulated up to 15.7-fold more 131I-FIAU, were growth inhibited by 2 μCi/ml, or 5 μCi/ml 131I-FIAU, and were inhibited by two log orders lower concentrations of GCV than parental cells. However, no synergy or additive effect was observed. Dose rate variations, or sequential treatment, did not alter outcome. Radioisotope therapy of HSV1-tk-expressing tumor cells with 131I-FIAU is reported for the first time. Lack of synergy between 131I-FIAU and GCV does not warrant further investigation of combination treatment with the two agents.

DOI: 10.1007/s11307-007-0078-3

6 Figures and Tables

Statistics

0501002008200920102011201220132014201520162017
Citations per Year

67 Citations

Semantic Scholar estimates that this publication has 67 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Schipper2007EvaluationOH, title={Evaluation of Herpes Simplex Virus 1 Thymidine Kinase-Mediated Trapping of 131I FIAU and Prodrug Activation of Ganciclovir as a Synergistic Cancer Radio/Chemotherapy}, author={Meike L. Schipper and Michael L. Goris and Sanjiv S. Gambhir}, journal={Molecular Imaging and Biology}, year={2007}, volume={9}, pages={110-116} }